Induction of Cardiac Pathology: Endogenous versus Exogenous Nrf2 Upregulation.
Bryan J MathisHideyuki KatoYuji HiramatsuPublished in: Cells (2022)
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of the endogenous antioxidant response to reactive oxygen species as well as a controller of Phase II detoxification in response to xenobiotics. This amenity to specific external manipulation exploits the binding affinity of Nrf2 for its constitutive repressor and degradation facilitator Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1). Derived from both natural and synthesized origins, these compounds have been extensively tested without definitive beneficial results. Unfortunately, multiple terminated trials have shown a negative side to Nrf2 with regard to cardiac pathologies while animal-based studies have demonstrated cardiomyocyte hypertrophy and heart failure after chronic Nrf2 upregulation. Putatively based on autophagic control of Nrf2 activity-modulating upstream factors, new evidence of miRNA involvement has added complexity to this mechanism. What follows is an extensive survey of Nrf2-regulating exogenous compounds that may promote cardiomyopathy, clinical trial evidence, and a comparison to exercise-induced factors that also upregulate Nrf2 while preventing cardiac pathologies.
Keyphrases
- oxidative stress
- clinical trial
- heart failure
- phase ii
- nuclear factor
- left ventricular
- signaling pathway
- reactive oxygen species
- cell death
- poor prognosis
- transcription factor
- small molecule
- cross sectional
- radiation therapy
- endothelial cells
- protein protein
- atrial fibrillation
- binding protein
- study protocol
- amino acid